Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1291583 (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2018
At a glance
- Drugs BI 1291583 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 19 Mar 2018 Planned End Date changed from 14 May 2018 to 13 Jun 2018.
- 19 Mar 2018 Planned primary completion date changed from 14 May 2018 to 13 Jun 2018.
- 07 Feb 2018 Status changed from not yet recruiting to recruiting.